How to use Technologies searched

A search for a company looking for a cancer, preclinical stage, synthetic opportunity would use the selection "Biomedicine, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform technology' in 'Sector' will identify all kinds of searches for technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each search profile gives the name or a short description of the company behind the search, and a link allowing to contact your potential licensee.

Registered users can create non-public notifications profiles which will inform them about new Technologies Searched entries fitting their expertise as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

RTI is looking for compound libraries for a free, confidential screening for anti-TB activity

Organization name

RTI International

Profile

RTI International (RTI) is an independent, nonprofit organization dedicated to improving the human condition through innovative research and effective technical assistance. Established in 1958, RTI is the second largest nonprofit research organization in the United States.

For more than 30 years, RTI has provided technology assessment and commercialization services for government and industry and has conducted research and development that addresses global health needs.  

As part of the National Institute for Allergy and Infectious Disease (NIAID) TB Drug Development Program, RTI actively facilitates partnerships between biotechnology companies, research labs, foundations, and international organizations to cooperatively develop, test, and introduce new drugs for the treatment of tuberculosis (TB).

NIAID has established a consortium of drug discovery and development resources that serve to:  

  • Stimulate biotechnology company investment in TB drug development.
  • Reduce risks and costs associated with the development process.

NIAID supports these efforts through its own laboratory research as well as through support to universities and other research organizations. All groups collaborate with industry to integrate drug development expertise in the programs.    

RTI is supported by NIAID to assist biotechnology companies by providing:  

  • Access to free, confidential screening services to test anti-infective compound libraries for anti-TB activity. NIAID services for nonclinical and clinical development may also be available for promising lead compounds.
  • Assistance in identifying and establishing discussions with partners to aid in the development of a promising anti-TB compound. These partnerships may represent either licensing or joint development opportunities.
  • Comparisons of the technical data between a promising lead compound and other TB drugs.
  • Recommendations for high-priority, near-term development activities.

RTI offers free, confidential screening of anti-infective compound libraries for anti-TB activity. Promising leads from these screens may result in licensing or co-development agreements where to NIAID resources for nonclinical and clinical development is available. 

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries